Log In
BCIQ
Print this Print this
 

MCLA-158

  Manage Alerts
Collapse Summary General Information
Company Merus N.V.
DescriptionAntibody-dependent cell-mediated cytotoxicity (ADCC)-enhanced human common light chain bispecific IgG1 antibody targeting leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5; GPR49) and EGFR
Molecular Target Leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5) (GPR49) ; Epidermal growth factor receptor (EGFR)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPreclinical
Standard IndicationSolid tumors
Indication DetailsTreat solid tumors
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today